Blinatumomab is a bi-specific T-cell engager antibody that has dual specificity for CD19 and CD3, bringing T cells in close proximity to CD19-positive ALL cells thus facilitating cytotoxic tumour cell killing. Here, CD19 is linked to neoplasm.